Cargando…
Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma
INTRODUCTION: Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and more than 90% of kidney neoplasms. High rates of undiagnostic percutaneous kidney biopsies and difficulties in reliable pre-operative differentiation between malignant and benign renal tumors using contemporary imagin...
Autores principales: | Mytsyk, Yulian, Dosenko, Victor, Skrzypczyk, Michał Andrzej, Borys, Yuriy, Diychuk, Yuriy, Kucher, Askold, Kowalskyy, Vasyl, Pasichnyk, Serhyi, Mytsyk, Oleh, Manyuk, Lubov |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Polish Urological Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202627/ https://www.ncbi.nlm.nih.gov/pubmed/30386650 http://dx.doi.org/10.5173/ceju.2018.1618 |
Ejemplares similares
-
Value of the Diffusion-Weighted MRI in the Differential Diagnostics of Malignant and Benign Kidney Neoplasms – Our Clinical Experience
por: Mytsyk, Yulian, et al.
Publicado: (2014) -
Personalized management of prostate cancer: from molecular and imaging markers to radiogenomics
por: Mytsyk, Yulian, et al.
Publicado: (2022) -
Local recurrence of renal cell carcinoma after partial nephrectomy: applicability of the apparent diffusion coefficient of MRI as an imaging marker – a multicentre study
por: Mytsyk, Yulian, et al.
Publicado: (2022) -
MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin
por: Konoshenko, Maria, et al.
Publicado: (2022) -
Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?
por: Ryspayeva, Dinara, et al.
Publicado: (2022)